Fig. 5: Injection of H-sEVs increases tumor ECM1 levels, cancer growth and metastasis in CD-fed 4T1-bearing mouse model. | Nature Communications

Fig. 5: Injection of H-sEVs increases tumor ECM1 levels, cancer growth and metastasis in CD-fed 4T1-bearing mouse model.

From: Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions

Fig. 5: Injection of H-sEVs increases tumor ECM1 levels, cancer growth and metastasis in CD-fed 4T1-bearing mouse model.The alternative text for this image may have been generated using AI.

a Location of the injected 4T1 cells in the mammary fat pad of the female BALB/c mice (upper panel indicated by an arrow) and accumulation of the tail vein injected DIR-labeled sEVs in the mammary pad of the mice (lower panel). b A schematic diagram showing the sEVs treatment protocol. c Protein expressions of ECM1, MMP3 and S100A/B in tumors of CD-fed 4T1-bearing BALB/c mice after C-sEVs or H-sEVs treatments. d Tumors, e tumor size, f tumor weight and g lung metastasis of the CD-fed 4T1-bearing BALB/c mice after the sEVs treatments. Mouse tumor sizes are presented as the mean ± SEM, other data are presented as mean ± SD; two-sided unpaired t-test for (c, f, g); n = 7 mice in each group; p values are indicated in graphs. C-sEVs, circulating sEVs in CD-fed BALB/c mice; H-sEVs, circulating sEVs in HFD-fed BALB/c mice; ECM1 extracellular matrix protein 1; MMP3 matrix metallopeptidase 3. Source data are provided as a Source Data file.

Back to article page